Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jun 15, 2006 (Vol. 26, No. 12)

aWare Biotech/Pharma Edition

  • Very interesting approach
  • May be hard to interpret
Want the scoop on where the biotech industry is headed? If you’re a stock market player interested in biotech, you probably do. Short of insider trading, what can you do? One approach is the rather awkwardly named aWare Biotech/Pharma Edition site that uses web-mining techniques to analyze corporate job advertising in an attempt to uncover market directions and R&D strategies, sales/licensing prospects, investment opportunities, and job market trends. Whew! Is that a tall order or what? Visitors to the site can select topics or companies and look at rankings of topic areas or trends in hiring/advertising, etc., over selected time periods. There is an amazing amount of data being analyzed, and a good deal of the site appears to be free. A site almost certain to appear on the bookmark list of biotech investors.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »